|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2010-5-26
|
|
pubmed:abstractText |
The aims of the present study were to investigate the pharmacokinetic and pharmacodynamic (pk/pd) relationship of levodopa (l-dopa) in patients with advanced Parkinson disease (PD) and also to evaluate the effect of tolcapone on the pk/pd analysis of l-dopa in 1 patient with severe dyskinesias and fluctuations.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/3-methoxytyrosine,
http://linkedlifedata.com/resource/pubmed/chemical/Antiparkinson Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Benserazide,
http://linkedlifedata.com/resource/pubmed/chemical/Benzophenones,
http://linkedlifedata.com/resource/pubmed/chemical/Carbidopa,
http://linkedlifedata.com/resource/pubmed/chemical/Catechol O-Methyltransferase,
http://linkedlifedata.com/resource/pubmed/chemical/Dopa Decarboxylase,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations,
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Levodopa,
http://linkedlifedata.com/resource/pubmed/chemical/Nitrophenols,
http://linkedlifedata.com/resource/pubmed/chemical/Tyrosine,
http://linkedlifedata.com/resource/pubmed/chemical/benserazide, levodopa drug...,
http://linkedlifedata.com/resource/pubmed/chemical/carbidopa, levodopa drug combination,
http://linkedlifedata.com/resource/pubmed/chemical/tolcapone
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1537-162X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
33
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
135-41
|
|
pubmed:meshHeading |
pubmed-meshheading:20216409-Age of Onset,
pubmed-meshheading:20216409-Aged,
pubmed-meshheading:20216409-Antiparkinson Agents,
pubmed-meshheading:20216409-Benserazide,
pubmed-meshheading:20216409-Benzophenones,
pubmed-meshheading:20216409-Carbidopa,
pubmed-meshheading:20216409-Catechol O-Methyltransferase,
pubmed-meshheading:20216409-Dopa Decarboxylase,
pubmed-meshheading:20216409-Drug Combinations,
pubmed-meshheading:20216409-Drug Therapy, Combination,
pubmed-meshheading:20216409-Dyskinesias,
pubmed-meshheading:20216409-Enzyme Inhibitors,
pubmed-meshheading:20216409-Female,
pubmed-meshheading:20216409-Half-Life,
pubmed-meshheading:20216409-Humans,
pubmed-meshheading:20216409-Levodopa,
pubmed-meshheading:20216409-Male,
pubmed-meshheading:20216409-Metabolic Clearance Rate,
pubmed-meshheading:20216409-Middle Aged,
pubmed-meshheading:20216409-Models, Biological,
pubmed-meshheading:20216409-Nitrophenols,
pubmed-meshheading:20216409-Parkinson Disease,
pubmed-meshheading:20216409-Severity of Illness Index,
pubmed-meshheading:20216409-Tyrosine
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
|
|
pubmed:affiliation |
Departments of Pharmacokinetics and Therapeutic Drug Monitoring, Pomeranian Medical University, Szczecin, Poland.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, N.I.H., Extramural
|
